glp-1 agonists in development Market Overview: and the Obesity Market | Blog GLP-1 Receptor Agonists and Research

doi: 10.1159/000485776 32 ShahZKampfrathTDeiuliisJAZhongJPinedaCYingZet al

D., Klammt, S., Posch, M

Published clinical trial data suggests retatrutide produces more pronounced metabolic effects than earlier-generation compounds in the populations studied

Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways

The Advanced Glycation End-Products (AGE)-Receptor for AGE System (RAGE): An Inflammatory Pathway Linking Obesity and Cardiovascular Diseases

There is a strong association between NAFLD and the metabolic syndrome with higher risk of NASH in those with underlying diabetes or obesity